Magnetic resonance imaging based clinical research in Alzheimer's disease

Journal of Alzheimer's Disease

Volumn 31, Issue SUPPL. 3, 2012, Pages

  Fayed, Nicolás ^a   Modrego, Pedro J ^b   Salinas, Gulillermo Rojas ^a   Gazulla, José ^b  

^a HOSPITAL QUIRÓN   (Spain)

^b HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

Author keywords

Alzheimer's disease; diffusion; functional; magnetic resonance; monitoring of treatment; perfusion; spectroscopy; structural image

Indexed keywords

BIOLOGICAL MARKER;

ALZHEIMER DISEASE; DEMENTIA; DIAGNOSTIC ACCURACY; DIFFUSION TENSOR IMAGING; DIFFUSION WEIGHTED IMAGING; HUMAN; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATIENT MONITORING; PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE;

EID: 84866856165     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2011-111292     Document Type: Review

References (122)

1. Wimo A, Prince M, UK Alzheimer's Disease International World Alzheimer Report (2010) The Global Economic Impact of Dementia. Published by Alzheimer's Disease International (ADI). http://www.alz.co.uk/research/files/ WorldAlzheimerReport2010.pdf
2. Carr D, Goate A, Phil D, Morris JC (1997) Current concepts in the pathogenesis of Alzheimer's disease. Am J Med 103, 3S-10S.
3. Petrella JR, Coleman RE, Doraiswamy PM (2003) Neuroimaging and early diagnosis of Alzheimer disease: A look to the future. Radiology 226, 315-336.
4. Petersen RC, Doody R, Kurz A (2001) Current concepts in mild cognitive impairment. Arch Neurol 58, 1985-1992.
5. Petersen R, Roberts R, Knopman D, Boeve B, Geda Y, Ivnik R, Smith G, Jack C (2009) Mild cognitive impairment ten years later. Arch Neurol 66, 1447-1455.
6. Braak H, Braak E (1991) Neuropathological staging of Alzheimer-related changes. Acta Neuropathol 82, 239-259.
7. Esiri MM (2001) An effective immune intervention for Alzheimer's disease in prospect? Trends Pharmacol Sci 22, 2-3.
8. Turner RS (2003) Biomarkers of Alzheimer's disease and mild cognitive impairment: Are we there yet? Exp Neurol 183, 7-10.
9. Wahlund LO (1996) Magnetic resonance imaging and computed tomography in Alzheimer's disease. Acta Neurol Scand 168, 50-53.
10. Smith CD (1996) Quantitative computed tomography and magnetic resonance imaging in aging and Alzheimer's disease: A review. J Neuroimaging 6, 44-53.
11. Burns A (1993) Computed tomography in Alzheimer's disease. Lancet 341, 601-602.
12. Scheltens P, Weinstein HC, Leys D (1992) Neuroimaging in the diagnosis of Alzheimer's disease. I. Computer tomography and magnetic resonance imaging. Clin Neurol Neurosurg 94, 277-289.
13. DeCarli C, Kaye JA, Horwitz B, Rapoport SI (1990) Critical analysis of the use of computer-assisted transverse axial tomography to study human brain in aging and dementia of the Alzheimer type. Neurology 40, 872-883.
14. Valenzuela MJ, Sachdev P (2001) Magnetic resonance spectroscopy in AD. Neurology 56, 592-598.
15. Rhinehart DL, Cox LA, Long BW (1998) MR spectroscopy of Alzheimer disease. Radiol Technol 70, 23-28.
16. Bartzokis G, Sultzer D, Lu PH, Nuechterlein KH, Mintz J, Cummings JL (2004) Heterogeneous age-related breakdown of white matter structural integrity: Implications for cortical "disconnection" in aging and Alzheimer's disease. Neurobiol Aging 25, 843-851.
17. Bartzokis G (2004) Age-related myelin breakdown: A developmental model of cognitive decline and Alzheimer's disease. Neurobiol Aging 25, 5-18.
18. Connor JR, Snyder BS, Arosio P, Loeffler DA, LeWitt P (1995)Aquantitative analysis of isoferritins in select regions of aged, parkinsonian, and Alzheimer's diseases brains. J Neurochem 65, 717-724.
19. Loeffler DA, Connor JR, Juneau PL, Snyder BS, Kanaley L, DeMaggio AJ, Nguyen H, Brickman CM, LeWitt PA(1999) Transferrin and iron in normal, Alzheimer's disease, and Parkinson's disease brain regions. J Neurochem 65, 710-716.
20. Sperling RA, Aisen PS, Beckett LA, Bennet DA, Craft S, Fagan AM, Iwatsubo T, Jack CR, Kaye J, Montine TJ, Park DC, Reiman EM, Siemers E, Rowe CC, Yaffe K, Carrillo MC, Stern Y, Thies B, Morrison-Bogorad M, Wagster MV, Phelps CH (2011) Toward defining the preclinical stages of Alzheimer's disease: Recommedations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7, 280-292.
21. O'Brien JT, Desmond P, Ames D, Schweitzer I, Chiu E, Tress B (1997) Temporal lobe magnetic resonance imaging can differentiate Alzheimer's disease from normal ageing, depression, vascular dementia and other causes of cognitive impairment. Psychol Med 27, 1267-1275.
22. Kelemen A, Székely G, Gerig G (1999) Morphometric model-based segmentation of 3-D Neuroradiological data sets. IEEE Trans Med Imaging 18, 828-839.
23. Ghiso J, Tomidokoro Y, Revesz T, Frangione B, Rostagno A (2010) Cerebral amyloid angiopathy and Alzheimer's disease. Hirosaki Med J 61(Suppl), S11-S124.
24. McEvoy L, Fennema-Notestine C, Cooper Roddey J, Hagler D, Holland D, Karow D, Pung C, Brewer J, Dale A (2009) For the Alzheimer's Disease Neuroimaging Initiative Alzheimer Disease: Quantitative structural neuroimaging for detection and prediction of clinical and structural changes in mild cognitive impairment. Radiology 251, 195- 205.
25. Desikan R, Cabral H, Hess C, Dillon W, Glastonbury C, Weiner M, Schmansky N, Greve D, Salat D, Buckner R, Fischl B (2009) Alzheimer's Disease Neuroimaging Initiative. Automated MRI measures identify individuals with mild cognitive impairment and Alzheimer's disease. Brain 132, 2048-2057.
26. Barnes J, Boyes R, Lewis E, Schott J, Frost C, Scahill R, FoxN(2007) Automatic calculation of hippocampal atrophy rates using a hippocampal template and the boundary shift integral. Neurobiol Aging 28, 1657-1663.
27. Jack C, Petersen R, Xu Y, Waring S, O'Brien P, Tangalos E (1997) Medial temporal atrophy on MRI in normal aging and very mild Alzheimer's disease. Neurology 49, 786-794.
28. Jack CR Jr, Petersen RC, Xu Y, O'Brien PC, Smith GE, Ivnik RJ (2000) Rates of hippocampal atrophy correlate with change in clinical status in aging and AD. Neurology 55, 484-489.
29. Erten-Lyons D, Howieson D, Moore MM, Quinn J, Sexton G, Silbert L (2006) Brain volume loss in MCI predicts dementia. Neurology 66, 233-235.
30. Barnes J, Bartlett J, Van de Pol L, Loy C, Scahill R, Frost C, Thompson P, Fox NC (2009) A meta-analysis of hippocampal atrophy rates in Alzheimer's disease. Neurobiol Aging 30, 1711-1723.
31. Morey R, Petty C, Xu Y, Pannu Hayes J,Wagner HR, Lewis D, LaBar K, Styner M, McCarthyG(2009)Acomparison of automated segmentation and manual tracing for quantifying hippocampal and amygdale volumes. Neuroimage 45, 855- 866.
32. Hua X, Leow A, Lee S, Klunder A, Toga A, Lepore N, Chou Y, Brun C, Chiang M, Barysheva M, Jack C, Bernstein M, Britson P, Ward C, Whitwell J, Borowski B, Fleisher A, Fox N, Boyes R, Barnes J, Harvey D, Kornak J, Schuff N, Boreta L, Alexander G, Weiner M, Thompsona P (2008) The Alzheimer's disease Neuroimaging Initiative. 3D characterization of brain atrophy in Alzheimer's disease and mild cognitive impairment using tensor-based morphometry. Neuroimage 41, 19-34.
33. Courtney SM, Ungerleider LG, Keil K, Haxby JV (1997) Transient and sustained activity in a distributed neural system for human working memory. Nature 86, 608-611.
34. Aguirre GK (2006) Interpretation of clinical functional neuroimaging studies. In: Functional MRI: Applications in clinical neurology and psychiatry, Mark D'Esposito, ed Informa Healthcare, Abingdon, pp. 9-24.
35. Cohen NJ, Ryan J, Hunt C, Romine L, Wszalek T, Nash C (1999) Hippocampal system and declarative (relational) memory: Summarizing the data from functional neuroimaging studies. Hippocampus 9, 83-98.
36. Puce A, Allison T, Gore JC, McCarthy G (1995) Facesensitive regions in human extrastriate cortex studied by functional MRI. J Neurophysiol 74, 1192-1199.
37. Petrella JR, Coleman RE, Doraiswamy PM (2003) Neuroimaging and early diagnosis of Alzheimer disease: A look to the future. Radiology 226, 315-336.
38. Saykin AJ, Flashman LA, Frutiger SA, Johnson SC, Mamourian AC, Moritz CH (1999) Neuroanatomic substrates of semantic memory impairment in Alzheimer's disease: Patterns of functional MRI activation. J Int Neuropsychology Soc 5, 377-392.
39. Dickerson BC, Salat DH, Bates JF, Atiya M, Killiany RJ, Greve DN (2004) Medial temporal lobe function and structure in mild cognitive impairment. Ann Neurol 56, 27-35.
40. Castillo M, Mukherji SK (2000) Diffusion-weighted imaging in the evaluation of intracranial lesions. Semin Ultrasound CT MR 21, 405-416.
41. Ramani A, Jensen JH, Helpern JA (2006) Quantitative MR imaging in Alzheimer disease. Radiology 241, 26-44.
42. Kantarci K, Jack CR Jr, Xu YC, Campeau NG, O'Brien PC, Smith GE (2001) Mild cognitive impairment and Alzheimer disease: Regional diffusivity of water. Radiology 219, 101- 107.
43. Hanyu H, Sakurai H, IwamotoT,Takasaki M, Shindo H, Abe K(1998) Diffusion-weightedMRimaging of the hippocampus and temporal white matter in Alzheimer's disease. J Neurol Sci 156, 195-200.
44. Sandson TA, Felician O, Edelman RR, Warach S (1999) Diffusion-weighted magnetic resonance imaging in Alzheimer's disease. Dement Geriatr Cogn Disord 10, 166-171.
45. Kantarci K, Petersen RC, Boeve BF, Knopman DS,Weigand SD, O'Brien PC (2005) DWI predicts future progression to Alzheimer disease in amnestic mild cognitive impairment. Neurology 64, 902-904.
46. Pierpaoli C, Jezzard P, Basser PJ, Barnett A, Di Chiro G (1996) Diffusion tensor MR imaging of the human brain. Radiology 201, 637-648.
47. Taber KH, Cortelli P, Staffen W, Hurley RA (2002) The expanding role of imaging in prion disease. J Neuropsychiatry Clin Neurosci 14, 371-376.
48. Huang J, Friedland RP, Auchus AP (2007) Diffusion tensor imaging of normal-appearing white matter in mild cognitive impairment and early Alzheimer disease: Preliminary evidence of axonal degeneration in the temporal lobe. AJNR Am J Neuroradiol 28, 1943-1948.
49. Zhang Y, Schuff N, Jahng G, Bayne W, Mori S, Schad L, Mueller S,DuT, Kramer J,YaffeK, Chui H, JagustW, Miller B, Weiner M (2007) Diffusion tensor imaging of cingulum fibers in mild cognitive impairment and Alzheimer disease. Neurology 68, 13-19.
50. Fayed-Miguel N, Castillo-Blandino J, Medrano-Lin J (2010) Perfusion by magnetic resonance imaging: Its physical foundations and clinical application. Rev Neurol 50, 23-32.
51. Harris GJ, Lewis RF, Satlin A, English CD, Scott TM, Yurgelun-Todd DA (1998) Dynamic susceptibility contrast MRimaging of regional cerebral blood volume in Alzheimer disease: A promising alternative to nuclear medicine. AJNR Am J Neuroradiol 19, 1727-1732.
52. Johnson NA, Jahng GH, Weiner MW, Miller BL, Chui HC, Jagust WJ, Gorno-Tempini ML, Schuff N (2005) Pattern of cerebral hypoperfusion in Alzheimer disease and mild cognitive impairment measured with arterial spin-labeling MR imaging: Initial experience. Radiology 234, 851-859.
53. Chao LL, Shannon W, Buckley ST, Kornak J, Schuff N, Madison C, Yaffe K, Miller B, Kramer J, Weiner M (2010) ASL perfusion MRI predicts cognitive decline and conversion from MCI to dementia. Alzheimer Dis Assoc Disord 24, 19-27.
54. Hashimoto M, Yasuda M, Tanimukai S, Matsui M, Hirono N, Kazui H, Mori E (2001) Apolipoprotein E epsilon 4 and the pattern of regional brain atrophy in Alzheimer's disease. Neurology 57, 1461-1466.
55. Greenberg SM, Tennis MK, Brown LB, Gomez-Isla T, Hayden DL, Schoenfeld DA, Walsh KL, Corwin C, Daffner KR, Friedman P, Meadows ME, Sperling RA, Growdon JH (2000) Donepezil therapy in clinical practice:Arandomized crossover study. Arch Neurol 57, 94-99.
56. Kantarci K, Jack CR Jr, Xu YC, Campeau NG, O'Brien PC, Smith GE, Ivnik RJ, Boeve BF, Kokmen E, Tangalos EG, PetersenRC(2000) Regional metabolic patterns in mild cognitive impairment and Alzheimer's disease: A 1H MRS study. Neurology 55, 210-217.
57. Modrego PJ, Fayed N, Pina MA (2005) Conversion from mild cognitive impairment to probable Alzheimer's disease predicted by brain magnetic resonance spectroscopy. Am J Psychiatry 162, 667-675.
58. Godbolt AK, Waldman AD, MacManus DG, Schott JM, Frost C, Cipolotti L, Fox NC, Rossor MN (2006) MRS shows abnormalities before symptoms in familial Alzheimer disease. Neurology 66, 718-722.
59. Kantarci K, Xu Y, Shiung MM, O'Brien PC, Cha RH, Smith GE, Ivnik RJ, Boeve BF, Edland SD, Kokmen E, Tangalos EG, Petersen RC, Jack CR (2002) Comparative diagnostic utility of different MR modalities in mild cognitive impairment and Alzheimer's disease. Dement Geriatr Cogn Disord 14, 198-207.
60. Fayed N,Dávila J, Oliveros A, Castillo J, Medrano JJ (2008) Utility of different MR modalities in mild cognitive impairment and its use as a predictor of conversion to probable dementia. Acad Radiol 15, 1089-1098.
61. Fayed N, Dávila J, Oliveros A Jr, Medrano J, Castillo J (2010) Correlation of findings in advanced MR techniques with global severity scales in patients with some grade of cognitive impairment. Neurol Res 32, 157-165.
62. Schuff N, Capizzano AA, Du AT, Amend DL, O'Neill J, Norman D, Jagust WJ, Chui HC, Kramer JH, Reed BR, Miller BL, Yaffe K, Weiner MW (2003) Different patterns of N-acetylaspartate loss in subcortical ischemic vascular dementia and AD. Neurology 61, 358-364.
63. Kattapong VJ, Brooks WM, Wesley MH, Kodituwakku PW, Rosenberg GA (1996) Proton magnetic resonance spectroscopy of vascular- and Alzheimer-type dementia. Arch Neurol 53, 678-680.
64. Waldman AD, Rai GS, McConnell JR, Chaudry M, Grant D (2002) Clinical brain proton magnetic resonance spectroscopy for management of Alzheimer's and sub-cortical ischemic vascular dementia in older people. Arch Gerontol Geriatr 35, 137-142.
65. Shonk TK, Moats RA, Gifford P, Michaelis T, Mandigo JC, Izumi J, Ross BD (1995) Probable Alzheimer disease: Diagnosis with proton MR spectroscopy. Radiology 195, 65-72.
66. Ernst T, Chang L, Melchor R, Mehringer CM (1997) Frontotemporal dementia and early Alzheimer disease: Differentiation with frontal lobe H-1 MR spectroscopy. Radiology 203, 829-836.
67. MacKay S, Ezekiel F, Di Sclafani V, Meyerhoff DJ, Gerson J, Norman D, Fein G, Weiner MW (1996) Alzheimer disease and subcortical ischemic vascular dementia: Evaluation by combining MR imaging segmentation and H-1 MR spectroscopic imaging. Radiology 198, 537-554.
68. MacKay S, Meyerhoff DJ, Constans JM, Norman D, Fein G, Weiner MW (1996) Regional gray and white matter metabolite differences in subjects with AD, with subcortical ischemic vascular dementia, and elderly controls with 1H magnetic resonance spectroscopic imaging. Arch Neurol 53, 167-174.
69. Firbank MJ, Harrison RM, O'Brien JT (2002) A comprehensive review of proton magnetic resonance spectroscopy studies in dementia and Parkinson's disease. Dement Geriatr Cogn Disord 14, 64-76.
70. Kantarci K, Smith GE, Ivnik RJ, Petersen RC, Boeve BF, Knopman DS, Tangalos EG, Jack CR (2002) 1H magnetic resonance spectroscopy, cognitive function, and apolipoprotein E genotype in normal aging, mild cognitive impairment and Alzheimer's disease. J Int Neuropsychol Soc 8, 934-942.
71. Kantarci K, Knopman DS, DicksonDW, Parisi JE, Whitwell JL,Weigand SD, Josephs KA, Boeve BF, Petersen RC, jack CR (2008) Alzheimer disease: Postmortem neuropathologic correlates of antemortem 1H MR spectroscopy metabolite measurements. Radiology 248, 210-220.
72. Mandal PK (2007) Magnetic resonance spectroscopy (MRS) and its application in Alzheimer's disease. Concepts Magn Reson Part A 30, 40-65.
73. Mandal PK (2011) In vivo proton magnetic resonance spectroscopic signal processing for the absolute quantitation of brain metabolites. Eur J Radiol 81, e653-e664.
74. Mandal PK,AkolkarH(2011)Anewexperimental approach and signal processing scheme for the detection and quantitation of 31P brain neurochemicals from in vivo MRS studies using dual tuned (1H/31P) head coil. Biochem Biophys Res Commun 412, 302-306.
75. Gillard J, Waldman A, Barker P (2005) Clinical MR neuroimaging diffusion, perfusion and spectroscopy. Cambridge University Press. Chapter III: p. 38.
76. Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) (2008) Guideline on Medicinal Products for the Treatment of Alzheimer's disease and Other Dementias. London Doc. Ref. CPMP/EWP/553/95 Rev. http://www.emea.europa.eu/docs/en GB/document library/Scientific guideline/2009/09/WC500003562.pdf, Posted 24 July 2008.
77. Smith AD (2002) Imaging the progression of Alzheimer pathology through the brain. Proc Natl Acad Sci U S A 99, 4135-4137.
78. Ridha BH, Barnes J, Bartlett JW, Godbolt A, Pepple T, Rossor MN, Fox NC (2006) Tracking atrophy progression in familial Alzheimer's disease: A serial MRI study. Lancet Neurol 5, 828-834.
79. Modrego PJ (2006) The effect of drugs for Alzheimer disease assessed by means of neuroradiological techniques. Curr Med Chem 13, 3417-3424.
80. Jack CR Jr, Slomkowski M, Gracon S, Hoover TM, Felmlee JP, Stewart K, Xu Y, Shiung M, O'Brien PC, Cha R, Knopman DS, Petersen RC (2003) MRI as a biomarker of disease progression in a therapeutic trial of milameline for AD. Neurology 60, 253-260.
81. Fox NC, Schott JM (2004) Imaging cerebral atrophy: Normal ageing to Alzheimer's disease. Lancet 363, 392-394.
82. Hashimoto M, Kazui H, Nakano Y, Yasuda M, Mori E (2005) Does donepezil treatment slow the progression of hippocampal atrophy in patients with Alzheimer's disease? Am J Psychiatry 162, 676-682.
83. Wang L, Harms MP, Staggs JM, Xiong C, Morris JC, Csernasky JG, Galvin JE (2010) Donepezil treatment and changes in hippocampal structure in very mild Alzheimer's disease. Arch Neurol 67, 99-106.
84. Schuff N, Suhy J, Goldman R, Xu Y, Sun Y, Truran-Sacrey D, Murthy A (2011) A MRI substudy of a donepezil clinical trial in mild cognitive impairment. Neurobiol Aging 32, 2318.e31-41.
85. Nobili F, Koulibaly M, Vitali P, Migneco O, Mariani G, Ebmeier K, Pupi A, Robert PH, Rodriguez G, Darcourt J (2002) Brain perfusion follow-up in Alzheimer's patients during treatment with acetyl cholinesterase inhibitors. J Nucl Med 43, 983-990.
86. Nobili F, Vitali P, Canfora M, Girtler N, De Leo C, Mariani G, Pupì A, Rodriguez G (2002) Effects of long-term donepezil therapy on rCBF of Alzheimer's patients. Clin Neurophysiol 113, 1241-1248.
87. Satlin A, Bodick N, Offen WW, Renshaw PF (1997) Brain proton magnetic resonance spectroscopy (1H-MRS) in Alzheimer's disease: Changes after treatment with xanomeline, an M1 selective cholinergic agonist. Am J Psychiatry 154, 1459-1461.
88. Frederick B, Satlin A, Wald LL, Hennen J, Bodick N, Renshaw PF (2002) Brain proton magnetic resonance spectroscopy in Alzheimer disease: Changes after treatment with xanomeline. Am J Geriatr Psychiatry 10, 81-88.
89. Krishnan RR, Charles HC, Doraiswamy PM, Mintzer J, Weisler R, Yu X, Perdomo C, Ieni JR, Rogers S (2003) Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer disease. Am J Psychiatry 160, 2003-2011.
90. Modrego PJ, Pina MA, Fayed N, Díaz M (2006) Changes in metabolite ratios after treatment with rivastigmine in Alzheimer's disease: A nonrandomized controlled trial with magnetic resonance spectroscopy. CNS Drugs 20, 867-887.
91. Modrego PJ, Fayed N, Errea JM, Rios C, Pina MA, Sarasa M (2010) Memantine versus donepezil in mild to moderate Alzheimer's disease: A randomized trial with magnetic resonance spectroscopy. Eur J Neurol 17, 405-412.
92. Birks J, Flicker L (2006) Donepezil for mild cognitive impairment. Cochrane Database Syst Rev 19, 3:CD006104.
93. Raschetti R, Albanese E, Vanacore N, Maggini M (2007) Cholinesterase inhibitors in mild cognitive impairment: A systematic review of randomised trials. PLoS Med 4, e338.
94. Petersen RC, Roberts RO, Knopman DS, Boeve BF, Geda YE, Ivnik RJ, Smith GE, Jack CR (2010) Mild cognitive impairment. Ten years later. Arch Neurol 66, 1447-1455.
95. Metastasio A, Rinaldi P, Tarducci R, Mariani E, Feliziani FT, Cherubini A, Pelliccioli GP, Gobbi G, Senin U, Mecossi P (2006) Conversion of MCI to dementia: Role of proton magnetic resonance spectroscopy. Neurobiol Aging 27, 926- 932.
96. Kantarci K, Weigand SD, Przybelski SA, Shiung MM, Whitwell JL, Negash S, Knopman DS, Boeve BF, O'Brien PC, Petersen RC, Jack CR (2009) Risk of dementia in MCI. Combined effect of cerebrovascular disease, volumetric MRI, and 1H MRS. Neurology 72, 1519-1525.
97. Modrego PJ, Fayed N, Sarasa M. Magnetic resonance spectroscopy in the prediction of early conversion from amnestic mild cognitive impairment to dementia. BMJOpen 2011; 1: e000007. doi 101136-bmjopen-2010-000007
98. Jack CR, Petersen RC, Xu YC, O'Brien PC, Smith GE, Ivnik RJ, Boeve BF, Waring SC, Tangalos EG, Kokmen E (1999) Prediction of AD with MRI based hippocampal volume in mild cognitive impairment. Neurology 52, 1397-1403.
99. Killiany RJ, Gómez-Isla T, Moss M, Kikinis R, Sandor T, Jolesz F, Tanzi R, Jones K, Hyman BT, Albert MS (2000) Use of structural magnetic resonance imaging to predict who will get Alzheimer's disease. Ann Neurol 47, 430-433.
100. Dickerson BC, Goncharova I, Sullivan MP, Forchetti C, Wilson RS, Bennet DA, Beckett LA, de Toledo-Morrel L (2001) MRI-derived entorhinal and hippocampal atrophy in incipient and very mild AD. Neurobiol Aging 22, 747-754.
101. Visser PJ, Verhey FR, Hofman PA, Scheltens P, Jolles JP (2002) Medial temporal lobe atrophy predicts Alzheimer's disease in mild cognitive impairment. J Neurol Neurosurg Psychiatry 72, 491-497.
102. Korf ES,Wahlund LO,Visser PJ, Scheltens P (2004) Medial temporal lobe on MRI predicts dementia in patients with mild cognitive impairment. Neurology 63, 94-100.
103. De Toledo-Morrell L, Stoub TR, Bulgakova M,Wilson RS, Bennet DA, Leurgans S, Wuu J, Turner DA (2004) MRIderived entorhinal volume is a good predictor of conversion from MCI to AD. Neurobiol Aging 25, 1197-1203.
104. Jack CR, Shiung MM,Weigand SD, O'Brien PC, Gunter JL, Boeve BF, Knopman DS, Smith GE, Ivnik RJ, Tangalos EG, Petersen RC (2005) Brain atrophy rates predict subsequent clinical conversion in normal elderly with amnestic MCI. Neurology 65, 1227-1231.
105. Stoub TR, Bulgakova M, Leurgans S, Bennet DA, Fleischman D, Turner DA, de Toledo-Morrel L (2005) MRI predictors of risk of incident Alzheimer's disease: A longitudinal study. Neurology 64, 1520-1524.
106. Devanand DP, Pradhaban G, Liu X, Khandji A, De Santi S, Segal S, Rusinek H, Pelton GH, Honig LS, Mayeux R, Stern Y, Tabert MH, de Leon MJ (2007) Hippocampal and entorhinal atrophy in mild cognitive impairment : Prediction of Alzheimer disease. Neurology 68, 828-836.
107. Landau SM, Harvey D, Madison CM, Reiman EM, Foster NL, Aisen PS, Petersen RC, Shaw LM, Trajanowski JQ, Jack CR, Weiner MW, Jagust WJ, ADNI (2010) Comparing predictors of conversion and decline in mild cognitive impairment. Neurology 75, 230-238.
108. Nho K, Shen L, Risacher SL, West JD, Foroud T, Jack CR, Weiner MW, Saykin AJ (2010) Automatic prediction of conversion from mild cognitive imapirment to probable Alzheimer's disease using structural magnetic resonance imaging. AMIA Annu Symp Proc 13, 542-546.
109. Karow D,McEvoy L, Fennema-Notestine C, Hagler D, Jennings R, Brewer J,HohC, DaleA(2010) For the Alzheimer's Disease Neuroimaging Initiative relative capability of MR imaging and FDG PET to depict changes associated with prodromal and early Alzheimer disease. Radiology 256, 932-994.
110. Vemuri P, Wiste H, Weigand S, Shaw L, Trojanowski J, Weiner M, Knopman D, Petersen R, Jack C (2009) MRI and CSF biomarkers in normal, MCI, and AD subjects Diagnostic discrimination and cognitive correlations. Neurology 73, 287-293.
111. Rabinovici GD, JagustWJ(2009) Amyloid imaging in aging and dementia: Testing the amyloid hypothesis in vivo. Behav Neurol 21, 117-128.
112. Jack CR, Lowe VJ, Weigand SD, Wiste HJ, Senjem ML, Knopman DS, Shiung MM, Gunter JL, Boeve BF, Kemp BJ, Weiner M, Petersen RC, ADNI (2009) Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: Implications for sequence of pathological events in Alzheimer's disease. Brain 132, 1355-1365.
113. Jack CR, Garwood M,Wengenack TM, Borowski B, Curran GL, Lin J, Adriany G, Gröhn OH, Grimm R, Podusio JF (2004) In vivo visualization of Alzheimer's amyloid plaques by magnetic resonance imaging in transgenic mice without a contrast agent. Magn Reson Med 52, 1263-1271.
114. Nakada T, Matsuzawa H, Igarashi H, Fujii Y, Kwee IL (2008) In vivo visualization of senile-plaque-like pathology in Alzheimer's disease patients by MR microscopy on a 7T system. J Neuroimaging 18, 125-129.
115. Yang J,Wadghiri YZ, Hoang DM, TsuiW, Sun Y, Chung E, Li Y, Wang A, de Leon M, Wisniewski T (2011) Detection of amyloid plaques targeted by USPIO-A-1-42 in Alzheimer's disease transgenic mice using magnetic resonance microimaging. Neuroimage 55, 1600-1609.
116. Green MA, Bilston LE, Sinkus R (2008) In vivo brain viscoelastic properties measured by magnetic resonance elastography. NMR Biomed 21, 755-764.
117. Mariappan YK, Glaser KJ, Ehman RL (2010) Magnetic resonance elastography: A review. Clin Anat 23, 497-511.
118. Knopman DS, DeKosky ST, Cummings JL, Chui H, Corey- Bloom J, Relkin N, Small GW, Miller B, Stevens JC (2001) Practice parameter: Diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 56, 1143-1153.
119. Petersen RC, Stevens JC, Ganguli M, Tangalos EG, Cummings JL, DeKosky ST (2001) Practice parameter: Early detection of dementia: Mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 56, 1133-1142.
120. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, Gamst A, Holtzman DM, Jagust WJ, Petersen RC, Snyder PJ, Carrillo MC, Thies B, Phelps CH (2011) The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations of the National Institute on aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7, 270-279.
121. Ioannidis JP (2011) Excess significance bias in the literature on brain volume abnormalities. Arch Gen Psychiatry 68, 773-780.
122. Mandal PK, Tripathi M, Sugunan S (2011) Detection and mapping of anti-oxidant marker glutathione in different human brain regions using non-invasive magnetic resonance spectroscopy. Biophy Biochem Res Commun 417, 43-48.